• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Modular epitope binding predicts influenza quasispecies dominance and vaccine effectiveness: Application to 2018/19 season

tetano

Editor, Senior Moderator
Vaccine. 2019 May 3. pii: S0264-410X(19)30417-7. doi: 10.1016/j.vaccine.2019.03.068. [Epub ahead of print]
[h=1]Modular epitope binding predicts influenza quasispecies dominance and vaccine effectiveness: Application to 2018/19 season.[/h] Bonomo ME[SUP]1[/SUP], Kim RY[SUP]2[/SUP], Deem MW[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The modular binding sites on the influenza A(H3N2) hemagglutinin protein are under significant pressure to acquire mutations in order to evade human antibody recognition. Analysis of these hemagglutinin epitopes in the strains circulating during 2017/18 and early 2018/19 identified the emergence of a new antigenic cluster that has grown from 4% of circulating strains to 11%. We regressed our module-based antigenic distance, p[SUB]epitope[/SUB], with A(H3N2) vaccine effectiveness from recent studies conducted by the US Centers for Disease Control and Prevention (r[SUP]2[/SUP] = 0.92), and we used this to estimate that the 2018/19 vaccines will protect against most circulating A(H3N2) strains. The pEpitope model is useful for A(H3N2) influenza vaccine virus selection and development, and it has the potential to aid national or regional regulatory authorities in making geographically localized decisions.
Copyright ? 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.


[h=4]KEYWORDS:[/h] Antigenic distance; Immunity; Mathematical models; Seasonal influenza; Vaccination planning; Vaccine effectiveness

PMID: 31060950 DOI: 10.1016/j.vaccine.2019.03.068
 
Back
Top Bottom